These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [New treatment options for HIV-infected patients]. Wehr A Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468 [No Abstract] [Full Text] [Related]
5. Anti-HIV agents. Atazanavir as a booster for protease inhibitors. TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850 [No Abstract] [Full Text] [Related]
6. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes. Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977 [TBL] [Abstract][Full Text] [Related]
8. CASTLE study showed similar efficacy. AIDS Patient Care STDS; 2008 Mar; 22(3):253. PubMed ID: 18348342 [No Abstract] [Full Text] [Related]
9. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing. Huff B GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962 [No Abstract] [Full Text] [Related]
10. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r]. MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981 [No Abstract] [Full Text] [Related]
11. A king in the CASTLE? Optimum initial HIV protease inhibitor. Torti C; Frank I Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849 [No Abstract] [Full Text] [Related]
12. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile]. MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065 [No Abstract] [Full Text] [Related]